OMEROS CORP OMER
- YARTEMLEA — Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy NDA Submitted
- YARTEMLEA — Acute Respiratory Distress Syndrome Phase 2
- OMS1029 Phase 1
- OMS1029 Phase 1
MASP-2 (1 companies · 4 programs)
Companies with an active program directed at MASP-2.